QIBA FDG-PET Biomarker Committee (BC) Call
03 March 2017 at 9 AM CT
Draft Call Summary

In attendance:

- Rathan Subramaniam, MD, PhD, MPH (co-chair)
- John Sunderland, PhD (co-chair)
- Scott Wollenweber, PhD (co-chair)
- Terry Brown
- Jerry Froelich, MD
- Howard Higley, PhD
- Paul Kinahan, PhD
- Martin Lodge, PhD
- Nancy Obuchowski, PhD
- Amy Perkins, PhD
- Eric Perlman, MD
- Ramkumar Saptharishi, PhD
- Anne Smith, PhD
- Na Sun, PhD
- Mitsuaki Tatsumi, MD
- Timothy Turkington, PhD
- Richard Wahl, MD
- Joe Koudelik
- Julie Lisiecki
- Joe Koudelik
- Julie Lisiecki

RSNA

Moderator: Dr. Wollenweber

NIBIB Update (Dr. Kinahan)

- The current NIBIB contract ends in September 2017. All funds are presently allocated.
- Due to other NIBIB funding/grant obligations, additional funding for QIBA is not available for 2017-2018
- QIBA leadership is considering applying for a no-cost extension to allow for existing research work to fully utilize existing funds for more in-depth research and analysis
- Potential may exist for supplemental NIBIB grant funding for individual PIs; QIBA leadership will be exploring this option in the future
- No additional projects related to the FDG-PET Profile, are anticipated after Round-6
  - Two main activities/projects have been funded, including the groundwork study for the field test and the DRO
- Dr. Wollenweber noted that QIBA leadership has re-invigorated the Sustainability Task Force, led by Dr. Annette Schmid, and hopes that many new ideas will come forth from the group

Profile Status

- Practical implementation of technical verification for the Profile was discussed
- Discussion points included:
  - How to gather and use data to test the claims
  - Endpoints of the study
  - Timing for test-re-test studies
  - Using advanced reconstruction techniques
  - Detective response function
  - How readings are done?
  - How to document that the checklist was followed accurately?
  - How to recruit sites
  - What correlations must be considered?
- These questions must be considered for the next Profile phase – clinical confirmation
- A mechanism is needed for the analysis
- The BC is considering 5 sites with 10 patients per site as an ideal “mini- clinical trial” that would move the Profile to the next phase
- Statistical input is needed
- Another possibility may involve working with a collaborative partner (e.g. ACR), or joining an existing study

Other

- Dr. Perkins reminded the group regarding outstanding DICOM changes that were proposed to the current format description for line 956
- Dr. Kinahan will follow up with Dr. Perkins offline

Nuclear Medicine WebEx Schedule:

Mar 10: Amyloid BC
Mar 17: SPECT BC
Mar 24: NM Leadership / TBD
Apr 07: FDG-PET BC